Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype - PubMed (original) (raw)
. 1996 Dec;5(12):1875-85.
doi: 10.1093/hmg/5.12.1875.
D J Smith, K McCutcheon, H B Koide, K Nishiyama, M B Dinulos, M E Stevens, N Bissada, J Nasir, I Kanazawa, C M Disteche, E M Rubin, M R Hayden
Affiliations
- PMID: 8968738
- DOI: 10.1093/hmg/5.12.1875
Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype
J G Hodgson et al. Hum Mol Genet. 1996 Dec.
Abstract
Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in exon 1 of a novel gene. The HD protein (huntingtin) plays a critical role in early embryonic development since homozygous targeted disruption of the murine HD gene results in embryonic lethality by day 7.5. To rescue this phenotype by transgene based huntingtin expression it is therefore essential to express the protein early enough in development in the appropriate cells. Since YAC based transgenes are known to be regulated in an appropriate temporal and tissue-specific manner, we sought to rescue the embryonic lethality by breeding YAC transgenic mice expressing human huntingtin with mice heterozygous for the targeted disruption. We generated viable offspring homozygous for the disrupted murine HD gene but expressing human huntingtin derived from the YAC. This result clearly shows that YAC transgene based expression of huntingtin occurs prior to 7.5 days gestation. Additionally, we show that human huntingtin expression in YAC transgenic mice follows an identical tissue distribution and subcellular localisation pattern as that of the murine endogenous protein and that expression levels of 2-3 times endogenous can be achieved. This shows that human huntingtin under the influence of its native promoter, despite differences to the murine protein, is functional in a murine background and can compensate for loss of the murine protein. These results show that YAC transgenic approaches are a particularly promising route to producing an animal model for disorders associated with CAG expansion.
Similar articles
- Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.
Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR. Leavitt BR, et al. Am J Hum Genet. 2001 Feb;68(2):313-24. doi: 10.1086/318207. Epub 2000 Dec 20. Am J Hum Genet. 2001. PMID: 11133364 Free PMC article. - Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM, Warby SC, Hayden MR. Van Raamsdonk JM, et al. Brain Res Bull. 2007 Apr 30;72(2-3):124-31. doi: 10.1016/j.brainresbull.2006.10.018. Epub 2006 Nov 16. Brain Res Bull. 2007. PMID: 17352936 Review. - Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA. Reddy PH, et al. Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45. doi: 10.1098/rstb.1999.0456. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434303 Free PMC article. - Huntington disease: new insights on the role of huntingtin cleavage.
Wellington CL, Leavitt BR, Hayden MR. Wellington CL, et al. J Neural Transm Suppl. 2000;(58):1-17. doi: 10.1007/978-3-7091-6284-2_1. J Neural Transm Suppl. 2000. PMID: 11128600 Review. - Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.
White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, MacDonald ME. White JK, et al. Nat Genet. 1997 Dec;17(4):404-10. doi: 10.1038/ng1297-404. Nat Genet. 1997. PMID: 9398841
Cited by
- Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
Essa MM, Moghadas M, Ba-Omar T, Walid Qoronfleh M, Guillemin GJ, Manivasagam T, Justin-Thenmozhi A, Ray B, Bhat A, Chidambaram SB, Fernandes AJ, Song BJ, Akbar M. Essa MM, et al. Neurotox Res. 2019 Apr;35(3):739-774. doi: 10.1007/s12640-018-9989-9. Epub 2019 Jan 11. Neurotox Res. 2019. PMID: 30632085 Review. - Size matters: use of YACs, BACs and PACs in transgenic animals.
Giraldo P, Montoliu L. Giraldo P, et al. Transgenic Res. 2001 Apr;10(2):83-103. doi: 10.1023/a:1008918913249. Transgenic Res. 2001. PMID: 11305364 Review. - Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease.
Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N. Pellman JJ, et al. J Neurochem. 2015 Aug;134(4):652-67. doi: 10.1111/jnc.13165. Epub 2015 Jun 4. J Neurochem. 2015. PMID: 25963273 Free PMC article. - Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.
Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR. Ehrnhoefer DE, et al. Acta Neuropathol Commun. 2018 Mar 6;6(1):16. doi: 10.1186/s40478-018-0518-0. Acta Neuropathol Commun. 2018. PMID: 29510748 Free PMC article. - Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.
Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR. Leavitt BR, et al. Am J Hum Genet. 2001 Feb;68(2):313-24. doi: 10.1086/318207. Epub 2000 Dec 20. Am J Hum Genet. 2001. PMID: 11133364 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases